Redx Pharma Share Discussion Threads

[bermudashorts] 15/2/2024 07:21

paulscb

Redx have another $15m in potential near term milestones from the previous deals with Jazz and AstraZeneca.

[muchodinero] 13/2/2024 12:55

Looks like someone is hoovering up a few shares 🤔 I think the Polar Capital sale last week softened the share price for a few days?

[everready1] 07/2/2024 19:56

is there a telegram group? link ? Thanks

[paulscb] 07/2/2024 19:49

Do people pay you in a telegram group for this research you do? Seriously?LOL

[paulscb] 07/2/2024 19:44

You may want to go study the 16 month gap between Jazz initial agreement and subsequent milestone payments on a different agreement here.

[babbler] 07/2/2024 18:04

And you know when the milestones are coming ? What they are? How much per milestone? This is the first of the promised news run this year. More to come.

[babbler] 07/2/2024 15:10

What's your point. You should see the major investment list here then you might sell APH for this. ;)

[blackhorse23] 07/2/2024 14:48

https://www.alliancepharmaceuticals.com/investors/shareholder-centre/significant-shareholders/

[olly353] 07/2/2024 09:55

Largest volume in over 3 years

[pdt] 07/2/2024 09:25

Great news today.The KRAS inhibitor program was peripheral to the main pipeline so a real bonus. That must extend cash out to the end of 2024. And give a potential milestone pipeline of some $1.5 billion in total. Two value inflection points over the next six months will be important in respect of ROCK inhibitor p2a in Fibrosis and porcupine p2 cancer candidate. The extended cash runway will not put them under pressure when partnering the latter if results are good.

Could this be the catalyst for a rerate. I think the recent trinity report had a target of 90p ??

[babbler] 07/2/2024 08:38

Give it up mate. Spamming all the boards daily with APH. No one cares.

[blackhorse23] 07/2/2024 08:18

Money moving to APH

[volsung] 08/3/2023 08:52

Beware,Beware, Beware all small pharma
Alack and alas many have trod this way to Hades before
Their souls litter the path..
Follow them not…

[pejaten] 23/2/2023 09:18

umm. terms seem unfair to REDX

[knitcraft] 04/9/2022 14:59

Put RXC004 into your search Engine then refer to my last post.

It gives real hope for specialist cancer and fibrosis treatment of previously extremly hard to treat tumours.

.....and potentially will give you the opportunity to buy into RedX before the news is widely available as to just who is responsible for this potential life-saving research.

[knitcraft] 04/9/2022 14:37

The following news item was first published in The "I" last week and has been subsequently picked up by other publications and TV news. The link below is to an ITV news item.

The intriguing and very important information that is missing from all the items, is the name of the company doing the research on RXC004.

It happens to be RedX and when that fact becomes widely known I would expect a reassessment of the value of RedX.

In June Trinity Delta,a reputable research company specialising in biomedicals, valued RedX shares on an undiluted basis at £1.38. The share price is currently 60p. Redx has at least 4 very promising research streams on the go.

From the research note in June 2022
Redx Pharma continues to deliver, with H122 results highlighting broad progress across the pipeline. The lead assets, RXC004, a porcupine inhibitor for oncology, and RXC007, a ROCK2 inhibitor for fibrosis, are advancing through Phase II and Phase I trials respectively, with further value inflection expected during 2022-23. Milestone receipts from AstraZeneca and Jazz Pharmaceuticals are tangible evidence of further progress with partnered programmes. Selection of RXC008, a GI targeted ROCK inhibitor as the next development candidate demonstrates earlier stage development is similarly bearing fruit. Our new rNPV-based valuation, updated to reflect H122 results and the May £34.3m (gross) equity raise, is £458m (vs £434m), or 138p/share.

It is worth looking at the company in more detail to fully appreciate what they are about. Look at the highly qualified team that has been assembled. Also check the lines of research they are pursuing and the major pharmaceutical companies they are associated with.
Also have look at the major shareholders involved.

Now look at this. Very few know this is about RedX. I suspect they soon will!

[knitcraft] 11/1/2022 11:00

Looking ready for a breakout on the up side.

[wapper] 23/12/2021 07:39

Another great Milestone payment RNS. Well done REDX and Merry Christmas all holders.

[wapper] 09/12/2021 08:29

UK, 9 December 2021 - Redx (AIM: REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, today announces that a milestone payment from Jazz Pharmaceuticals (NASDAQ: JAZZ) has been triggered as a result of entering the second year of the oncology research collaboration with the Company.

The milestone payment of $10 million arises in accordance with the terms of the research collaboration agreement announced on 9 September 2020. Under the agreement to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase (MAPK) pathway, Redx is responsible for research and preclinical development activities up to Investigational New Drug (IND) submission. In addition to the $20 million in payments that have now been realised, Redx may receive up to a further $200 million from Jazz in development, regulatory and commercial milestone payments for each programme. The next milestone is payable upon successful IND submission and all subsequent milestones are contingent on successful completion of the relevant stages of development. In addition, Redx is eligible for tiered royalties in mid-single digit percentages, based on any future net sales.

Lisa Anson, Chief Executive Officer of Redx, commented: "We are extremely pleased to extend our productive oncology research collaboration with Jazz into its second year. This is based on advancing our programmes in this key signalling pathway and reflects Redx's core strength in discovering highly targeted potential drug candidates. We look forward to further progress in partnership with Jazz."

Redx continues to execute on its strategy, progressing its lead oncology and fibrosis programmes. These include the oral Porcupine inhibitor, RXC004, targeting Wnt-ligand driven tumours, which has recently entered a Phase 2 trial in genetically selected patients with microsatellite stable metastatic colorectal cancer (MSS mCRC) and the oral selective ROCK2 inhibitor, RXC007, being developed for idiopathic pulmonary fibrosis, where first in human studies commenced in June 2021.

[knitcraft] 15/9/2021 10:45

Completely different management these days. Seem to be doing a great job. Statement next week is expected to be very positive. Tremendous potential to make a difference to Cancer and Fibrosis treatment. It will all take time to materialise but is well worth the wait as a shareholder.

[latifs100] 14/9/2021 21:16

gutted sold at 70p